Arbutus Biopharma Corporation Stock News

Moderna stock tumbled late Thursday after the biotech lost a patent battle that could jeopardize the financial future of its coronavirus vaccine. Moderna denies a threat to vaccine profits.

A simple two-rule screen can help you pick R&D-intensive stocks primed to outperform. The differences between R&D expenditures and capital expenditures vary bet

In this article we will take a look at whether hedge funds think Arbutus Biopharma Corp (NASDAQ:ABUS) is a good investment right now. We check hedge fund and billionaire investor sentiment before delv

WARMINSTER, Pa., May 27, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic.

The biotech sector remains in focus with pipeline updates on coronavirus treatments.

In the current session, Arbutus Biopharma Inc. (NASDAQ: ABUS) is trading at $2.43, after a 29.79% increase. Over the past month, the stock increased by 103.10%, and in the past year, by 16.12%. With p

Arbutus Biopharma Corporation (ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today reports positive follow-u

Celebrations may be in order for Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders, with the analysts...

Arbutus (ABUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

As of late, it has definitely been a great time to be an investor in Arbutus Biopharma.

Given the troubling state of the U.S. economy, what’s driving the bullish sentiment on Wall Street? Stimulus.Among the bulls is chief investment strategist at CFRA, Sam Stovall, who estimates that t

WARMINSTER, Pa., May 12, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic.

Arbutus Biopharma Corporation (ABUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Arbutus (ABUS) delivered earnings and revenue surprises of 21.88% and -17.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of Arbutus Biopharma (NASDAQ:ABUS) rose 12.6% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 46.81% year over year to ($0.25), which beat